OncoMark - Breast Cancer
RATHER targets untreatable and aggressive forms of Breast Cancer
Funded by the EU Commission's FP7 Programme of Research & Development.
Breast cancer is a disease that presents great emotional, social, economical and clinical problems world-wide. There is a crucial need to develop more targeted therapies and marker systems for breast cancer. More information can be found at www.targetbreast.com and www.ratherproject.com.
RATHER is a consortium project funded by the European Commission's 7th Framework Programme of Research and Development.
The project will focus on two specific difficult-to-treat subtypes of breast cancer.
- Invasive Lobular Carcinoma in situ (ILC) is a type of localised cancer that occurs within the milk-producing lobules of the breast. It accounts for approximately 10% of cases of breast cancer globally.
- Triple Negative (TN) breast cancer is a metastatic subtype that lacks the estrogen, progesterone and HER2 receptors. It accounts for approximately 15% of cases.
At present, no targeted therapies are available for either of these diseases.
The RATHER consortium aims to better our understanding of these cancers by applying state-of-the-art investigative techniques to 300 clinical samples from patients with these diseases (150 ILC and 150 TN). RATHER website>>
Breast cancer is a disease that presents great emotional, social, economical and clinical problems world-wide. There is a crucial need to develop more targeted therapies and marker systems for breast cancer. The work activities of this consortium is hoped to have a significant impact on the development of novel diagnostics and therapeutics for breast cancer. The consortium comprises of academic and industry partners. Target Breast website>>